Journal of infection in developing countries · 2025
Comparing the clinical outcomes of Remdesivir and Interferon beta-1a in hospitalized COVID-19 patients: A cross-sectional retrospective single-center study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Asgari Mehrdad, Kousha Abolfazl, Ghaffari Mohammad Ebrahim, Yaghubi Kalurazi Tofigh, Zaminy Arash
Аннотация
INTRODUCTION: The effectiveness of remdesivir (RDV) and interferon beta-1a (IFNβ-1a) was assessed and compared in patients hospitalized with coronavirus disease of 2019 (COVID-19).
METHODOLOGY: A total of 162 hospitalized COVID-19 patients were divided into two groups: the RDV group and the IFNβ-1a group. Through laboratory tests and a physical examination, the patient's clinical condition was evaluated.
RESULTS: RDV and IFNβ-1a treatments significantly decreased fever, cough, shortness of breath, and weakness in COVID-19 patients (All p < 0.001). RDV treatment significantly decreased shortness of breath, erythrocyte sedimentation rate (ESR), and creatinine, relative to IFNβ-1a treatment (p < 0.03, p = 0.001, and p < 0.004, respectively). RDV treatment significantly decreased Lactate Dehydrogenase (LDH) in COVID-19 patients (p = 0.006). The mean time of hospitalization was 8.9 days in the RDV group and 8.2 days in the IFNβ-1a group. There was no statistical difference between the two groups. The IFNβ-1a group had a considerably lower rate of intensive care unit (ICU) admission than the RDV group (p = 0.006).
CONCLUSIONS: No difference in clinical outcomes was found between RDV and IFNβ-1a treatments. RDV was more effective than IFNβ-1a in moderating the inflammatory response in COVID-19 patients by reducing LDH and ESR. The IFNβ-1a group had a considerably lower rate of ICU admission than the RDV group.
METHODOLOGY: A total of 162 hospitalized COVID-19 patients were divided into two groups: the RDV group and the IFNβ-1a group. Through laboratory tests and a physical examination, the patient's clinical condition was evaluated.
RESULTS: RDV and IFNβ-1a treatments significantly decreased fever, cough, shortness of breath, and weakness in COVID-19 patients (All p < 0.001). RDV treatment significantly decreased shortness of breath, erythrocyte sedimentation rate (ESR), and creatinine, relative to IFNβ-1a treatment (p < 0.03, p = 0.001, and p < 0.004, respectively). RDV treatment significantly decreased Lactate Dehydrogenase (LDH) in COVID-19 patients (p = 0.006). The mean time of hospitalization was 8.9 days in the RDV group and 8.2 days in the IFNβ-1a group. There was no statistical difference between the two groups. The IFNβ-1a group had a considerably lower rate of intensive care unit (ICU) admission than the RDV group (p = 0.006).
CONCLUSIONS: No difference in clinical outcomes was found between RDV and IFNβ-1a treatments. RDV was more effective than IFNβ-1a in moderating the inflammatory response in COVID-19 patients by reducing LDH and ESR. The IFNβ-1a group had a considerably lower rate of ICU admission than the RDV group.